Dow Down0.02% Nasdaq Up0.07%

More On MOR.DE

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials


Morphosys AG (MOR.DE)

-XETRA
78.13 Down 0.58(0.74%) 11:35AM EST
ProfileGet Profile for:
Morphosys AG
Lena-Christ-Strasse 48
Martinsried, 82152
Germany - Map
Phone: 49 8989 9270
Fax: 49 89 8992 7222
Website: http://www.morphosys.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:328

Business Summary 

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies for therapeutic applications. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease. It operates therapeutic development programs for drug candidates in cooperation with various biotechnology and pharmaceutical companies, as well as focuses on the development of proprietary therapeutic antibodies. The company’s proprietary programs include MOR103, an antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis, as well as other proprietary clinical programs, including MOR202 and MOR208 for the treatment of cancer. It has strategic alliances with Novartis AG for the discovery and development of biopharmaceuticals; and Celgene Corporation for the development and co-promotion of the CD38 cancer program. The company was founded in 1992 and is headquartered in Martinsried, Germany.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Morphosys AG

Key Executives 
 PayExercised
Dr. Simon E. Moroney Ph.D.,
Chairman of Management Board and Chief Exec. Officer
951.00K0.00
Mr. Jens Holstein ,
Chief Financial Officer and Member of Management Board
630.00K0.00
Dr. Marlies Sproll , 56
Chief Scientific Officer and Member of Management Board
623.00K0.00
Dr. Arndt Schottelius , 48
Chief Devel. Officer and Member of Management Board
631.00K0.00
Mr. Klaus De Wall ,
Head of Accounting & Controlling
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in EUR.